Skip to main content
Premium Trial:

Request an Annual Quote

Indivumed nRavel

Individumed has introduced nRavel, an artificial intelligence-based multiomic informatics platform for precision oncology drug discovery. The new product adds a suite of analytics and machine learning tools to the company's multiomic cancer database, IndivuType, to assist target discovery and drug development for its pharmaceutical customers. The first release of nRavel features "toolboxes" for immuno-oncology, pathways and signaling, biomarkers, genomics, signatures, and clinical analytics. The Hamburg, Germany-based company said that it anticipates more applications in the future.